Drugs for Synovitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 109)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Rituximab |
Approved |
Phase 4 |
|
174722-31-7 |
|
Synonyms:
ABP-798
ANTICD20
CT-P10
HS006
HS-006
HS-006 (RITUXIMAB BIOSIMILAR)
HSDB 7455|IDEC-C2B8|MabThera®|Rituxan®
IDEC-102
IDEC-C2B8
IG GAMMA-1 CHAIN C REGION
Ig gamma-2A chain C region, membrane-bound form
MABTHERA
MABTHERA RITUXAN
|
R-105 IDEC-102
radiolabeled murine anti-CD20
RG-105
RHCACD20MA
RITUXAN
RITUXIMAB
rituximab-abbs
rituximab-arrx
rituximab-pvvr
SAIT101
SAIT-101
Zevalin
|
|
2 |
|
Triamcinolone |
Approved, Vet_approved |
Phase 4 |
|
124-94-7 |
31307 |
Synonyms:
11b,16a,17a,21-Tetrahydroxy-9a-fluoro-1,4-pregnadiene-3,20-dione
11beta,16alpha,17alpha,21-Tetrahydroxy-9alpha-fluoro-1,4-pregnadiene-3,20-dione
11Β,16α,17α,21-tetrahydroxy-9α-fluoro-1,4-pregnadiene-3,20-dione
9a-Fluoro-11b,16a,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9a-Fluoro-11b,16a,17a,21-tetrahydroxypregna-1,4-diene-3,20-dione
9a-Fluoro-16a-hydroxyprednisolone
9alpha-Fluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9alpha-Fluoro-11beta,16alpha,17alpha,21-tetrahydroxypregna-1,4-diene-3,20-dione
9alpha-Fluoro-16alpha-hydroxyprednisolone
9-Fluoro-11b,16a,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9-Fluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9-Fluoro-11β,16α,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9Α-fluoro-11β,16α,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9Α-fluoro-11β,16α,17α,21-tetrahydroxypregna-1,4-diene-3,20-dione
9Α-fluoro-16α-hydroxyprednisolone
Adcortyl
Aristocort
ARISTOCORT A
Aristocort Tablets
Aristogel
Aristospan
Azmacort
Celeste
Cinolone
Cinolone-T
DELPHICORT
Fluoxiprednisolone
fluoxiprednisolone|Kenalog®|Nasacort®
Fluoxyprednisolone
Flutex
Fougera
Kenacort
Kenacort-A
Kenacort-Ag
KENALOG
Kenalog in Orabase
Kenalog-10
Kenalog-40
Kenalog-H
Ledercort
|
NASACORT
Nasacort Aq
Nasacort Hfa
NSC-13397
Omcilon
Omicilon
Oracort
Oralone
Orion
Polcortolon
Rodinolone
Sk-Triamcinolone
TIAMCINOLONUM
Tiamcinolonum [INN-Latin]
Triacet
Triacort
Triamcet
Triamcinalone
Triamcinlon
Triamcinolon
Triamcinolona
Triamcinolona [INN-Spanish]
TRIAMCINOLONE
Triamcinolone acetonide
Triamcinolone diacetate
Triamcinolone hexacetonide
Triamcinolonum
Triamcinolonum [INN]
Triam-Tablinen
Triatex
Tricortale
Triderm
Trilone
Tri-Nasal
Tristoject
Trymex
Vetalog
Volon
Volon A
|
|
3 |
|
Mometasone furoate |
Approved, Investigational, Vet_approved |
Phase 4 |
|
83919-23-7 |
4240 441336 |
Synonyms:
(9BETA,10ALPHA,11ALPHA,14BETA,16ALPHA,17ALPHA)-9,21-DICHLORO-11-HYDROXY-16-METHYL-3,20-DIOXOPREGNA-1,4-DIEN-17-YL FURAN-2-CARBOXYLATE
ASMANEX
ASMANEX HFA
ASMANEX TWISTHALER
ELOCON
MOMETASONE
MOMETASONE 17-FUROATE
|
MOMETASONE FUROATE
Mometasone furoate anhydrous
MOMETASONE FUROATE MONOHYDRATE
Mometasone furoic acid
NASONEX
SCH-32088
SINUVA
|
|
4 |
|
Upadacitinib |
Approved, Investigational |
Phase 4 |
|
1310726-60-3 |
76829165 58557659 |
Synonyms:
3-Ethyl-4-{1,5,7,10-tetraazatricyclo[7.3.0.0,]dodeca-2(6),3,7,9,11-pentaen-12-yl}-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboximidate
ABT-494
|
ABT-494|Rinvoq®
UPADACITINIB
|
|
5 |
|
Antineoplastic Agents, Immunological |
|
Phase 4 |
|
|
|
6 |
|
Melanocyte-Stimulating Hormones |
|
Phase 4 |
|
|
|
7 |
|
Adrenocorticotropic Hormone |
|
Phase 4 |
|
|
|
8 |
|
beta-Endorphin |
|
Phase 4 |
|
|
|
Synonyms:
|
9 |
|
Hormones |
|
Phase 4 |
|
|
|
10 |
|
Hormone Antagonists |
|
Phase 4 |
|
|
|
11 |
|
Triamcinolone hexacetonide |
|
Phase 4 |
|
|
|
Synonyms:
ARISTOSPAN
CL-34433
LEDERSPAN
|
TATBA
TRIAMCINOLONE HEXACETONIDE
|
|
12 |
|
Triamcinolone diacetate |
|
Phase 4 |
|
|
|
Synonyms:
ARISTOCORT
KENACORT
ORION
POLCORTOLON
|
TEDAROL
TRIAMCINOLONE 16,21-DIACETATE
TRIAMCINOLONE DIACETATE
|
|
13 |
|
Triamcinolone Acetonide |
|
Phase 4 |
|
|
6436 |
Synonyms:
ADCORTYL
ADCORTYL IN ORABASE
ALLERNAZE
ARISTOCORT
ARISTOCORT A
ARISTOGEL
AUDICORT
AUREOCORT
AZMACORT
FLUTEX
GPPE EAR DPS CAP
GPPE EAR OINT
KENACORT
KENACOURT
KENALOG
KENALOG IN ORABASE
KENALOG-10
KENALOG-40
KENALOG-80
KENALOG-H
NASACORT
NASACORT ALLERGY 24 HOUR
NASACORT AQ
|
NASACORT HFA
NSC-21916
NYSTADERMAL
ORACORT
ORALONE
PEVARYL T.C.
REMIDERM
REMOTIC
SILDERM
TRIACET
TRIACORT
TRI-ADCORTYL
TRIAMCINOLONE ACETONIDE
TRIAMCINOLONE ACETONIDE IN ABSORBASE
TRIATEX
TRIDERM
TRIESENCE
TRI-NASAL
TRIVARIS
TRYMEX
VETALOG
ZILRETTA
Zilretta®
|
|
14 |
|
glucocorticoids |
|
Phase 4 |
|
|
|
15 |
|
Anti-Inflammatory Agents |
|
Phase 4 |
|
|
|
16 |
|
BAX 855 |
|
Phase 4 |
|
|
|
17 |
|
Factor VIII |
|
Phase 4 |
|
|
|
18 |
|
Coagulants |
|
Phase 4 |
|
|
|
19 |
|
Tumor Necrosis Factor Inhibitors |
|
Phase 4 |
|
|
|
20 |
|
Janus Kinase Inhibitors |
|
Phase 4 |
|
|
|
21 |
|
Protein Kinase Inhibitors |
|
Phase 4 |
|
|
|
22 |
|
Etanercept |
Approved, Investigational |
Phase 3 |
|
185243-69-0 |
|
Synonyms:
BENEPALI
CD120B
ENBREL
Enbrel Sureclick
Etanercept
etanercept-szzs
etanercept-ykro
FC
GP2015
GP-2015
GP2015C
HD203
L04AB01
|
LBEC0101
P75
P80 TNF-ALPHA RECEPTOR
Recombinant human TNF
RHU TNFR
rhu TNFR:Fc
rhu-TNFR:Fc
TNF-R2
TNFR-Immunoadhesin
TUMOR NECROSIS FACTOR RECEPTOR 2
TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY MEMBER 1B PRECURSOR
TUMOR NECROSIS FACTOR RECEPTOR TYPE II
|
|
23 |
|
Abatacept |
Approved |
Phase 3 |
|
332348-12-6 |
|
Synonyms:
ABATACEPT
ABATACEPT (GENETICAL RECOMBINATION)
Abatacept recombinant
BMS-188667
BMS-188667|CTLA4-IgG4m|Orencia®|RG-1046|RG-2077
CTLA4IG
CTLA4-IG
|
CTLA4IGG4M
CTLA4-IGG4M
ORENCIA
ORENCIA CLICKJECT
RG-1046
RG-2077
|
|
24 |
|
Betamethasone |
Approved, Vet_approved |
Phase 3 |
|
378-44-9 |
9782 |
Synonyms:
16beta-Methyl-1,4-pregnadiene-9alpha-fluoro-11beta,17alpha,21-triol-3,20-dione
16b-Methyl-1,4-pregnadiene-9a-fluoro-11b,17a,21-triol-3,20-dione
16Β-methyl-1,4-pregnadiene-9α-fluoro-11β,17α,21-triol-3,20-dione
9a-Fluoro-16b-methylprednisolone
9alpha-Fluoro-16beta-methylprednisolone
9-Fluoro-16beta-methylprednisolone
9-Fluoro-16b-methylprednisolone
9-Fluoro-16β-methylprednisolone
9Α-fluoro-16β-methylprednisolone
ALPHATREX
BESAMESTAZONA
Betadexamethasone
Betametasona
BETAMETHASONE
Bétaméthasone
beta-Methasone alcohol
Betamethasonum
BETAMETHASONVALERAT MIKRON
BETASOLAN
|
BETATREX
BETA-VAL
BETNELAN
b-Methasone alcohol
Celeston
Celestona
Celestone
Cellestoderm
DERMABET
Flubenisolone
LOTRISONE
NSC-39470
Rinderon
SCH-4831
TACLONEX
UTICORT
VISUBETA
Î’-methasone alcohol
|
|
25 |
|
Certolizumab pegol |
Approved |
Phase 3 |
|
428863-50-7 |
|
Synonyms:
|
CERTOLIZUMAB PEGOL
CIMZIA
PHA-738144
|
|
26 |
|
Dronabinol |
Approved, Illicit |
Phase 3 |
|
1972-08-3 |
16078 |
Synonyms:
&Delta
Δ<sup>9</sup>-THC|Abbott 40566|delta9-THC|Marinol®|tetrahydrocannabinol|THC
(-)- delta 9-Tetrahydrocannabinol
(-)-3,4-trans-delta1-Tetrahydrocannabinol
(-)-3,4-trans-Δ1-Tetrahydrocannabinol
(-)-delta 1-Tetrahydrocannabinol
(-)-delta 9-THC
(-)-delta 9-trans-Tetrahydrocannabinol
(-)-delta1-Tetrahydrocannabinol
(-)-delta9-Tetrahydrocannabinol
(-)-delta9-THC
(-)-delta9-trans-Tetrahydrocannabinol
(-)-trans-delta 1-Tetrahydrocannabinol
(-)-trans-delta 9-Tetrahydrocannabinol
(-)-trans-delta 9-THC
(-)-trans-delta1-Tetrahydrocannabinol
(-)-trans-delta9-Tetrahydrocannabinol
(-)-trans-delta9-THC
(-)-trans-Δ1-Tetrahydrocannabinol
(-)-trans-Δ9-Tetrahydrocannabinol
(-)-trans-Δ9-THC
(-)-Δ1-Tetrahydrocannabinol
(-)-Δ9-Tetrahydrocannabinol
(-)-Δ9-THC
(-)-Δ9-trans-tetrahydrocannabinol
(L)-delta 1-Tetrahydrocannabinol
(l)-delta1-Tetrahydrocannabinol
(l)-Δ1-Tetrahydrocannabinol
14C-delta 1-Tetrahydrocannabinol
1-trans-delta 9-Tetrahydrocannabinol
1-trans-delta-9-Tetrahydrocannabinol
1-trans-Δ-9-tetrahydrocannabinol
3-Pentyl-6,6,9-trimethyl-6a,7,8,10a-tetrahydro-6H-dibenzo(b,D)pyran-1-ol
6,6,9-Trimethyl-3-pentyl-6a,7,8,10a-tetrahydro-6H-benzo[c]chromen-1-ol
6H-DIBENZO(B,D)PYRAN-1-OL, 6A,7,8,10A-TETRAHYDRO-6,6,9-TRIMETHYL-3-PENTYL-, (6AR,10AR)-
9 Ene tetrahydrocannabinol
9-Ene-tetrahydrocannabinol
9-tetrahydrocannabinol
9-THC
ABBOTT 40566
ABBOTT-40566
Dea No. 7369
Dea No. 7370
delta 1-Tetrahydrocannabinol
delta 1-THC
delta 9-Tetrahydrocannabinol
delta 9-THC
delta 9-trans-Tetrahydrocannabinol
Delta(1)-Tetrahydrocannabinol
delta(1)-THC
delta(9)-Tetrahydrocannabinol
Delta(9)-THC
delta1-Tetrahydrocannabinol
|
delta1-THC
delta9-Tetrahydrocannabinol
DELTA-9-TETRAHYDROCANNABINOL
delta9-THC
DELTA-9-THC
delta9-trans-Tetrahydrocannabinol
Deltanyne
Dronabinol
Dronabinol [Usan:Inn]
DRONABINOLEN
Dronabinolum
Dronabinolum [Latin]
Exocyclic delta (9)(11)-tetrahydrocannabiol
J882F
L-delta 1-trans-Tetrahydrocannabinol
l-delta1-trans-Tetrahydrocannabinol
L-trans-delta 9-Tetrahydrocannabinol
l-trans-delta9-Tetrahydrocannabinol
l-trans-Δ9-Tetrahydrocannabinol
l-Δ1-trans-Tetrahydrocannabinol
Marinol
NSC-134454
Primolut
QCD 84924
QCD-84924
Solvay brand OF tetrahydrocannabinol
SP 104
SP-104
Syndros
Tetrahydrocannabinol
Tetrahydrocannabinol, (6ar-cis)-isomer
Tetrahydrocannabinol, (6as-cis)-isomer
Tetrahydrocannabinol, (6a-trans)-isomer
Tetrahydrocannabinol, trans isomer
Tetrahydrocannabinol, trans-(+-)-isomer
Tetrahydrocannabinol, trans-isomer
THC
trans-(-)-delta9-Tetrahydrocannabinol
trans-(-)-Δ9-Tetrahydrocannabinol
trans-delta (-)-9-Tetrahydrocannabinol
trans-delta 9-Tetrahydrocannabinol
trans-delta9-Tetrahydrocannabinol
trans-Δ9-Tetrahydrocannabinol
Δ(1)-tetrahydrocannabinol
Δ(9)-THC
Δ1-Tetrahydrocannabinol
Δ1-THC
Δ9-tetrahydrocannabinol
Δ-9-tetrahydrocannabinol
Δ9-THC
Δ-9-THC
Δ9-trans-Tetrahydrocannabinol
|
|
27 |
|
Anti-Inflammatory Agents, Non-Steroidal |
|
Phase 3 |
|
|
|
28 |
|
Gastrointestinal Agents |
|
Phase 3 |
|
|
|
29 |
|
Anti-Arrhythmia Agents |
|
Phase 3 |
|
|
|
30 |
|
Sodium Channel Blockers |
|
Phase 3 |
|
|
|
31 |
|
Diuretics, Potassium Sparing |
|
Phase 3 |
|
|
|
32 |
|
Chondroitin |
|
Phase 3 |
|
9007-27-6 |
14389182 |
Synonyms:
2-Acetamido-2-deoxy-3-O-b-D-glucopyranuronosyl-b-D-galactopyranose
2-Acetamido-2-deoxy-3-O-beta-D-glucopyranuronosyl-beta-D-galactopyranose
2-Acetamido-2-deoxy-3-O-β-D-glucopyranuronosyl-β-D-galactopyranose
b-D-GlcA-(1->3)-b-D-galnac
b-D-GlcpA-(1->3)-b-D-galpnac
b-D-Glucuronosyl-(1->3)-2-acetamido-2-deoxy-b-D-galactose
beta-D-GlcA-(1->3)-beta-D-galnac
|
beta-D-Glucuronosyl-(1->3)-2-acetamido-2-deoxy-beta-D-galactose
Chondroitin
Chondroitin-D-glucuronate
N-Acetylchondrosine
Β-D-glca-(1->3)-β-D-galnac
Β-D-glcpa-(1->3)-β-D-galpnac
Β-D-glucuronosyl-(1->3)-2-acetamido-2-deoxy-β-D-galactose
|
|
33 |
|
Immune Checkpoint Inhibitors |
|
Phase 3 |
|
|
|
34 |
|
Anti-Asthmatic Agents |
|
Phase 3 |
|
|
|
35 |
|
Respiratory System Agents |
|
Phase 3 |
|
|
|
36 |
|
Analgesics, Non-Narcotic |
|
Phase 3 |
|
|
|
37 |
|
Analgesics |
|
Phase 3 |
|
|
|
38 |
|
Neurotransmitter Agents |
|
Phase 3 |
|
|
|
39 |
|
Psychotropic Drugs |
|
Phase 3 |
|
|
|
40 |
|
Hallucinogens |
|
Phase 3 |
|
|
|
41 |
|
Fludarabine |
Approved |
Phase 2 |
|
75607-67-9, 21679-14-1 |
30751 657237 |
Synonyms:
2-F-ARAA
2-F-Ara-A|CCRIS 3382|F-Ara-A|Fludara®
2F-Ara-AMP
2-fluoro ARA-A
2-Fluoroadenine arabinoside 5'-monophosphate
2-Fluoroadenine arabinoside 5'-monophosphoric acid
2-Fluoro-ara AMP
2-FLUORO-ARA-A
9 beta-D-Arabinofuranosyl-2-fluoroadenine monophosphate
9-b-Arabinofuranosyl-2-fluoroadenine-5'-phosphate
9-b-Arabinofuranosyl-2-fluoroadenine-5'-phosphoric acid
9-b-D-Arabinofuranosyl-2-fluoroadenine 5'-(dihydrogen phosphate)
9-b-D-Arabinofuranosyl-2-fluoroadenine 5'-(dihydrogen phosphoric acid)
9-b-D-Arabinofuranosyl-2-fluoroadenine 5'-monophosphate
9-b-D-Arabinofuranosyl-2-fluoroadenine 5'-monophosphoric acid
9-beta-Arabinofuranosyl-2-fluoroadenine-5'-phosphate
9-beta-Arabinofuranosyl-2-fluoroadenine-5'-phosphoric acid
9-beta-D-Arabinofuranosyl-2-fluoroadenine 5'-(dihydrogen phosphate)
9-beta-D-Arabinofuranosyl-2-fluoroadenine 5'-(dihydrogen phosphoric acid)
9-beta-D-Arabinofuranosyl-2-fluoroadenine 5'-monophosphate
9-beta-D-Arabinofuranosyl-2-fluoroadenine 5'-monophosphoric acid
9-Î’-arabinofuranosyl-2-fluoroadenine-5'-phosphate
9-Î’-arabinofuranosyl-2-fluoroadenine-5'-phosphoric acid
|
9-Î’-D-arabinofuranosyl-2-fluoroadenine 5'-(dihydrogen phosphate)
9-Î’-D-arabinofuranosyl-2-fluoroadenine 5'-(dihydrogen phosphoric acid)
9-Î’-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate
9-Î’-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphoric acid
Beneflur
FAMP
FaraAMP
F-Ara-AMP
Fludara
Fludarabina
FLUDARABINE
Fludarabine 5'-monophosphate
Fludarabine 5'-monophosphoric acid
Fludarabine monophosphate
Fludarabine monophosphoric acid
Fludarabine phosphate
Fludarabine phosphoric acid
Fludarabinum
Fludura
Fluoro-ara-AMP
NSC-312887
NSC-328002
OFORTA
|
|
42 |
|
Prednisolone phosphate |
Approved, Vet_approved |
Phase 2 |
|
302-25-0 |
|
Synonyms:
Prednisolone 21-(dihydrogen phosphate)
Prednisolone 21-monophosphate
|
Prednisolone 21-phosphate
|
|
43 |
|
Prednisolone acetate |
Approved, Vet_approved |
Phase 2 |
|
52-21-1 |
|
Synonyms:
ECONOPRED
FLO-PRED
METICORTELONE
NSC-10966
OMNIPRED
PRED FORTE
|
PRED FTE
PRED MILD
PREDNISOLONE 21-ACETATE
PREDNISOLONE ACETATE
STERANE
ULTRACORTENOL
|
|
44 |
|
Prednisolone |
Approved, Vet_approved |
Phase 2 |
|
50-24-8 |
4894 5755 |
Synonyms:
(11b)-11,17,21-Trihydroxypregna-1,4-diene-3,20-dione
(11beta)-11,17,21-Trihydroxypregna-1,4-diene-3,20-dione
(11Î’)-11,17,21-trihydroxypregna-1,4-diene-3,20-dione
1,4-Pregnadiene-11b,17a,21-triol-3,20-dione
1,4-Pregnadiene-11beta,17alpha,21-triol-3,20-dione
1,4-Pregnadiene-11β,17α,21-triol-3,20-dione
1,4-Pregnadiene-3,20-dione-11b,17a,21-triol
1,4-Pregnadiene-3,20-dione-11beta,17alpha,21-triol
1,4-Pregnadiene-3,20-dione-11β,17α,21-triol
3,20-Dioxo-11b,17a,21-trihydroxy-1,4-pregnadiene
3,20-Dioxo-11beta,17alpha,21-trihydroxy-1,4-pregnadiene
3,20-Dioxo-11β,17α,21-trihydroxy-1,4-pregnadiene
Ak-Pred
Ak-Tate
Alphadrol
Articulose-50
Codelcortone
Co-Hydeltra
Cordrol
CORTALONE
Cotogesic
Cotolone
Decaprednil
Decortin H
DEKOTIL
Delcortol
Delta F
Delta(1)-Dehydrocortisol
Delta(1)-Dehydrohydrocortisone
Delta(1)-Hydrocortisone
DELTA.1-CORTISOL
DELTA.1-Cortisol|Orapred®|Pediapred®
Delta-Cortef
Deltacortenol
DELTACORTRIL
Deltacortril Enteric
delta-dehydrocortisol
delta-dehydrohydrocortisone
delta-hydrocortisone
Deltahydrocortisone
DELTALONE
Deltasolone
Delta-Stab
Deltisilone
Depo-Medrol
Derpo Pd
DESOWEN
Dexa-Cortidelt Hostacortin H
Di adreson F
Di-Adreson F
Di-adreson-F
DiAdresonF
Dicortol
DILACORT
Donisolone
Dydeltrone
Eazolin D
Econopred
Econopred Plus
Erbacort
Erbasona
Estilsona
Fernisolone
Fernisolone P
FERNISOLONE-P
Flamasone
Hostacortin H
HYDELTRA
Hydeltrasol
HYDELTRA-TBA
Hydeltrone
Hydrodeltalone
Hydrodeltisone
Hydroretrocortin
Hydroretrocortine
IMS904
Inflamase Forte
Inflamase Mild
I-Pred
Key-Pred
Klismacort
Lentosone
Lite Pred
Medrol
|
Medrol Acetate
Metacortandralone
Methylprednisolone acetate
METICORTELONE
METI-DERM
Metreton
M-Predrol
NEO-DELTA-CORTEF
Nisolone
Nor-Pred T.B.A.
NSC-9120
NSC-9900
Ocu-Pred
Ocu-Pred Forte
Ophtho-Tate
ORAPRED
Panafcortelone
Paracortol
Paracotol
PEDIAPRED
PEVANTI
POLY-PRED
PRDL
Precortalon
Precortancyl
Precortilon
PRECORTISYL
PRECORTISYL FTE
Pred Forte
Pred Mild
Predair
Predair A
Predair Forte
Predalone 50
Predalone T.B.A.
Predate
Predate Tba
Predate-50
Predcor-25
Predcor-50
Predcor-Tba
PRED-G
Predisolone sodium phosphate
PREDL
Predne-Dome
Prednelan
Prednicen
Predni-Dome
Predniliderm
Predniretard
Prednis
Prednisolona
Prednisolona [INN-Spanish]
Prednisolone
Prednisolone acetate
Prednisolone sodium phosphate
Prednisolone tebutate
Prednisolonum
Prednisolonum [INN-Latin]
Predonin
Predonine
PRELONE
Prenolone
Rolisone
SCHERIPROCT
Scherisolon
SERVISONE
Solone
Steran
STERANE
Sterolone
Supercortisol
TRIDESILON
Ulacort
Ultra Pred
Ultracorten H
Ultracortene H
Ultracortene-H
Ultracortene-Hydrogen
VERDESO
Δ(1)-dehydrocortisol
Δ(1)-dehydrohydrocortisone
Δ(1)-hydrocortisone
Δ-cortef
|
|
45 |
|
Methylprednisolone hemisuccinate |
Approved |
Phase 2 |
|
2921-57-5 |
1875 |
Synonyms:
Methylprednisolone hemisuccinate
Methylprednisolone hemisuccinic acid
|
Methylprednisolone hydrogen succinate
Methylprednisolone succinate
|
|
46 |
|
Methylprednisolone |
Approved, Vet_approved |
Phase 2 |
|
83-43-2 |
4159 6741 |
Synonyms:
(6a,11b)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione
(6alpha,11beta)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione
(6Α,11β)-11,17,21-trihydroxy-6-methylpregna-1,4-diene-3,20-dione
1-Dehydro-6alpha-methylhydrocortisone
1-Dehydro-6a-methylhydrocortisone
1-Dehydro-6α-methylhydrocortisone
6 Methylprednisolone
6alpha-Methyl-11beta,17alpha,21-triol-1,4-pregnadiene-3,20-dione
6alpha-Methylprednisolone
6a-Methyl-11b,17a,21-triol-1,4-pregnadiene-3,20-dione
6a-Methylprednisolone
6-Methylprednisolone
6Α-methyl-11β,17α,21-triol-1,4-pregnadiene-3,20-dione
6Α-methylprednisolone
Artisone-Wyeth
Besonia
Delta(1)-6alpha-Methylhydrocortisone
delta(1)-6a-Methylhydrocortisone
Dopomedrol
Esametone
Firmacort
J3.872E
Lemod
Medesone
Medixon
Medlone 21
Medrate
Medric acid
Medrol
Medrol Adt Pak
Medrol Dosepak
Medrol®|U-67590A
Medrone
Mesopren
|
Metastab
Methyleneprednisolone
Methylprednisolon
Methylprednisolone
Methylprednisolonum
Methylprednisolonum [INN-Latin]
Metilbetasone
Metilprednisolona
Metilprednisolona [INN-Spanish]
Metilprednisolone
Metilprednisolone [Dcit]
Metipred
Metrisone
Metrocort
Metysolon
Moderin
Nirypan
Noretona
NSC-19987
Predni N Tablinen
Promacortine
Reactenol
Sieropresol
Solomet
SOLU-MEDROL
Summicort
Suprametil
U-67590A
Urbason
Urbasone
Wyacort
Δ(1)-6a-methylhydrocortisone
Δ(1)-6α-methylhydrocortisone
|
|
47 |
|
Ascorbic acid |
Approved, Nutraceutical |
Phase 2 |
|
50-81-7 |
54676860 54670067 5785 |
Synonyms:
(+)-Ascorbate
(+)-Ascorbic acid
(+)-Sodium L-ascorbate
[<sup>14</sup>C]-ascorbic acid
3-keto-L-Gulofuranolactone
3-oxo-L-Gulofuranolactone
AA
Acid, ascorbic
Acid, L-ascorbic
Acide ascorbique
Acido ascorbico
ácido ascórbico
Acidum ascorbicum
Acidum ascorbinicum
Adenex
Allercorb
Antiscorbic vitamin
Antiscorbutic vitamin
arco-Cee
Ascoltin
ASCOR
Ascorb
Ascor-b.i.d.
Ascorbajen
Ascorbate
Ascorbate radical
Ascorbate, ferrous
Ascorbate, magnesium
Ascorbate, sodium
ASCORBIC ACID
Ascorbic acid radical
Ascorbic acid, monosodium salt
Ascorbicab
Ascorbicap
Ascorbicin
Ascorbin
Ascorbinsaeure
Ascorbinsäure
Ascorbutina
Ascorin
Ascorteal
Ascorvit
Cantan
Cantaxin
Catavin C
Ce lent
Cebicure
Cebid
Cebion
Cebione
Cecon
Cee-caps TD
Cee-vite
Cegiolan
Ceglion
Ceklin
Celaskon
Celin
Cell C
Cemagyl
Ce-mi-lin
Cemill
Cenetone
Cenolate
Cereon
Cergona
Cescorbat
Cetamid
Cetane
Cetane-caps TC
Cetane-caps TD
Cetebe
Cetemican
Cevalin
Cevatine
Cevex
Cevi-bid
Cevimin
Ce-vi-sol
Cevital
Cevitamate
Cevitamic acid
Cevitamin
Cevitan
Cevitex
Cewin
Chewcee
|
Ciamin
Cipca
Citriscorb
Citrovit
C-Level
C-Long
Colascor
Concemin
C-Quin
C-Span
C-Vimin
Davitamon C
Di-L-ascorbate, magnesium
Dora-C-500
Duoscorb
e 300
e300
e-300
Ferrous ascorbate
gamma-Lactone L-threo-hex-2-enonate
gamma-Lactone L-threo-hex-2-enonic acid
HiCee
Hybrin
ido-C
Juvamine
Kangbingfeng
Kyselina askorbova
L Ascorbic acid
L(+)-Ascorbate
L-(+)-Ascorbate
L(+)-Ascorbic acid
L-(+)-Ascorbic acid
L-3-Ketothreohexuronic acid lactone
Laroscorbine
L-Ascorbate
L-Ascorbic acid
Lemascorb
Liqui-cee
L-Lyxoascorbate
L-Lyxoascorbic acid
L-threo-Ascorbic acid
L-Xyloascorbate
L-Xyloascorbic acid
Magnesium ascorbate
Magnesium ascorbicum
Magnesium di L ascorbate
Magnesium di-L-ascorbate
Magnorbin
Meri-c
Monodehydroascorbate radical
Monodehydroascorbic acid radical
Natrascorb
Natrascorb injectable
Planavit C
Proscorbin
Redoxon
Ribena
Ronotec 100
Rontex 100
Roscorbic
Rovimix C
Scorbacid
Scorbu C
Scorbu-C
Secorbate
Semidehydroascorbate
Semidehydroascorbic acid
Sodascorbate
Sodium ascorbate
Suncoat VC 40
Testascorbic
VASC
Vicelat
Vicin
Vicomin C
Viforcit
Viscorin
Viscorin 100m
Vitace
Vitacee
Vitacimin
Vitacin
Vitamin C
Vitamina C
Vitamisin
Vitascorbol
Xitix
|
|
48 |
|
Prednisolone hemisuccinate |
Experimental |
Phase 2 |
|
2920-86-7 |
4897 |
Synonyms:
(+)-prednisolone hemisuccinate
4-(2-{14,17-dihydroxy-2,15-dimethyl-5-oxotetracyclo[8.7.0.0,.0,]heptadeca-3,6-dien-14-yl}-2-oxoethoxy)-4-oxobutanoate
Prednisolonbisuccinat
Prednisolone 21-hemisuccinate
Prednisolone 21-succinate
|
Prednisolone bisuccinate
PREDNISOLONE HEMISUCCINATE
Prednisolone hemisuccinic acid
Prednisolone hydrogen succinate
PREDNISOLONE SUCCINATE
|
|
49 |
|
Grapefruit Seed Extract |
|
Phase 2 |
|
|
|
50 |
|
Vitamins |
|
Phase 2 |
|
|
|
Interventional clinical trials:
(show top 50)
(show all 63)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Targeting Synovitis in Early Rheumatoid Arthritis (TaSER). Intensive Management of Early Rheumatoid Arthritis Using Either Clinical or Musculoskeletal Ultrasound Assessment of Synovitis - a Randomised Study With Blinded Outcome Assessments |
Unknown status |
NCT00920478 |
Phase 4 |
|
2 |
Dosing of Intra-articular Triamcinolone Hexacetonide for Knee Synovitis in Chronic Polyarthritis |
Unknown status |
NCT02437461 |
Phase 4 |
Triamcinolone hexacetonide |
3 |
Study of The Effect of Corticotrophin in Combination With Methotrexate in Newly Diagnosed Rheumatoid Arthritis Patients From a Clinical and Structural Perspective As Measured by a Clinical Disease Activity Index Score and Bone Edema, Synovitis and Erosions on Magnetic Resonance Imaging |
Completed |
NCT01948388 |
Phase 4 |
corticotrophin 80 units |
4 |
Pilot Study to Evaluate the Effect of Mabthera in Combination With MTX in the Inhibition of Progression of Synovitis, Bone Marrow Edema, and Erosions Evaluated by Magnetic Resonance Imaging (MRI) in the Hand of Patients With Rheumatoid Arthritis. |
Completed |
NCT00502853 |
Phase 4 |
rituximab [MabThera/Rituxan];Methotrexate |
5 |
A Randomized, Double-blind, Placebo-controlled Study to Assess Efficacy of Tocilizumab+Non-biological DMARD in Reducing Synovitis as Measured by MRI at 12 Weeks After Initiation of Treatment in Patients With Moderate to Severe Rheumatoid Arthritis With Inadequate Response to Non-biological DMARDs |
Completed |
NCT01034397 |
Phase 4 |
tocilizumab [RoActemra/Actemra];placebo;non-biological DMARDs |
6 |
Injection After Arthroscopic Partial Meniscectomy |
Enrolling by invitation |
NCT04641351 |
Phase 4 |
Zilretta Injectable Product or Placebo |
7 |
Intensive Replacement Treatment in Haemophilia Patients With Synovitis |
Not yet recruiting |
NCT04784988 |
Phase 4 |
Adynovate;plasma derived or recombinant products containing FVIII |
8 |
Early Changes in Pain, Disease Activity, and Ultrasound Evidence of Inflammatory Synovitis in Patients Receiving JAK-inhibitor vs. TNF-inhibitor Therapy for Active Rheumatoid Arthritis: A Feasibility Study. |
Not yet recruiting |
NCT05153200 |
Phase 4 |
Upadacitinib;Adalimumab |
9 |
Adipose Derived Stromal Cell Transplantation as an Adjunct to Arthroscopy in Treatment of Effusion Synovitis of the Early Degenerative Knee |
Suspended |
NCT03922490 |
Phase 4 |
|
10 |
Open Label Study to Describe the Effect of Tocilizumab in Combination With MTX in the Evolution of Articular Damage (Synovitis/Osteitis and Erosions) Evaluated by MRI in the Hand of Patients With Moderate to Severe Rheumatoid Arthritis (RA) and Inadequate Response to Non-biological DMARDs |
Withdrawn |
NCT01878318 |
Phase 4 |
methotrexate;tocilizumab [RoActemra/Actemra] |
11 |
A Double-blind, Randomized, Placebo-controlled Phase 3 Study of Orally Administered PLX3397 in Subjects With Pigmented Villonodular Synovitis or Giant Cell Tumor of the Tendon Sheath |
Completed |
NCT02371369 |
Phase 3 |
Pexidartinib;Placebo |
12 |
Study of the Effect of Chondroitin Sulphate on Synovial Inflammation in Patients With Osteoarthritis of the Knee |
Completed |
NCT00604539 |
Phase 3 |
Chondroitin sulphate (Condrosan);Placebo |
13 |
A Phase IIIB Multicenter, Randomized, Double-Blind, Placebo-controlled Study to Assess Short-term Changes in Synovitis and Structural Damage Outcomes in Subjects With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate, Treated With Abatacept Versus Placebo on a Background Therapy With Methotrexate |
Completed |
NCT00420199 |
Phase 3 |
Abatacept;Placebo |
14 |
Intra-Articular Injection of Etanercept in Patient Suffering From Rheumatoid Arthritis : a Double-Blind Randomized Study for Evaluation of Efficacy and Safety of Etanercept Versus Intra-Articular Steroid Injection in Acute Synovitis |
Completed |
NCT00522184 |
Phase 3 |
|
15 |
Open Label, Multicentric Phase IIIb Study to Evaluate the Effect of Tocilizumab in Combination With DMARDs in the Inhibition of Progression of Synovitis, Bone Marrow Edema, and Erosions Evaluated by Dedicated Magnetic Resonance Imaging (MRI) in the Hand of Patients With Rheumatoid Arthritis (RA) |
Completed |
NCT00996606 |
Phase 3 |
DMARDs;Tocilizumab |
16 |
The Role of Intra-articular Injection of Autologous Platelet Rich Plasma Versus Corticosteriods in Treatment of Synovitis in Lumbar Facet Joint Disease |
Completed |
NCT04860531 |
Phase 3 |
Lumbar Facet Joints intra-articular injection with Platelet Rich Plasma;Lumbar Facet Joints intra-articular injection with a mixture of 0.5% lidocaine and 5mg/ml of betamethasone |
17 |
The Effect of Certolizumab Pegol in Combination With Methotrexate on MRI Synovitis and Bone Edema and Patient Reported Outcomes as Measured Using an Automated Visit Manager System in Moderate to Severe Rheumatoid Arthritis Patients |
Completed |
NCT01213017 |
Phase 3 |
certolizumab pegol |
18 |
A Phase 3, Randomized, Placebo-controlled, Double-blind Study of Vimseltinib to Assess the Efficacy and Safety in Patients With Tenosynovial Giant Cell Tumor (MOTION) |
Recruiting |
NCT05059262 |
Phase 3 |
vimseltinib;Placebo |
19 |
Dronabinol for the Treatment of Postoperative Pain After Arthroscopic Surgery: a Pilot Randomized Trial |
Recruiting |
NCT05335252 |
Phase 3 |
Dronabinol;Placebo |
20 |
A Phase II Randomized, Double -Blind, Placebo Controlled Study to Assess Safety, Tolerability and Effect on Tumor Size of MCS110 in Patients With Pigmented Villonodular Synovitis (PVNS) |
Completed |
NCT01643850 |
Phase 2 |
MCS110;Placebo |
21 |
A Phase 1/2 Study of Cabiralizumab, an Anti-CSF1 Receptor Antibody, in Patients With Pigmented Villonodular Synovitis (PVNS)/ Diffuse Type Tenosynovial Giant Cell Tumor (Dt-TGCT) |
Completed |
NCT02471716 |
Phase 1, Phase 2 |
|
22 |
Phase II Study of Nilotinib Efficacy in Pigmented Villo-Nodular Synovitis/ Tenosynovial Giant Cell Tumour (PVNS/TGCT) |
Completed |
NCT01261429 |
Phase 2 |
Tasigna |
23 |
Evaluation of The Efficacy And Safety of Intra-Articular Etanercept in Patients With Refractory Knee Joint Synovitis: a Placebo Controlled, Single-Blind, Crossover-Trial, With Randomisation of Treatment Sequence |
Completed |
NCT00678782 |
Phase 2 |
etanercept;placebo |
24 |
Methotrexate Alone Versus Combination of Methotrexate and Subcutaneous Fludarabine for Severe Rheumatoid Arthritis: Safety, Tolerance and Efficacy |
Completed |
NCT00001677 |
Phase 2 |
Methotrexate;Fludarabine |
25 |
A Prospective Double-Blinded Clinical Trial Using Apatone®B for Care and Treatment of Proven Non-Infected Symptomatic Postoperative Total Joint Arthroplasties |
Completed |
NCT01272830 |
Phase 2 |
Placebo;Apatone®B |
26 |
Impact of Rituximab on Magnetic Resonance Imaging Evidence of Synovitis and Bone Lesions in Patients With Moderate or Severe Rheumatoid Arthritis |
Completed |
NCT00425932 |
Phase 2 |
|
27 |
A Multicenter Phase 1/2, Open-Label Study of DCC-3014 to Assess the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor |
Recruiting |
NCT03069469 |
Phase 1, Phase 2 |
DCC-3014 |
28 |
MRI Evaluation Assessing Synovitis to Address the Unmet Need for Reliable Endpoints in SLE |
Recruiting |
NCT03355482 |
Phase 2 |
Methylprednisolone;Placebos |
29 |
A Phase 2, Adaptive, Open-Label, Multiple-Dose, Dose-Escalation Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Intravenous AMB-05X in Subjects With Tenosynovial Giant Cell Tumor |
Active, not recruiting |
NCT04938180 |
Phase 2 |
|
30 |
An Adaptive, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of Intra-articular AMB-05X Injections in Subjects With Tenosynovial Giant Cell Tumor of the Knee |
Active, not recruiting |
NCT04731675 |
Phase 2 |
|
31 |
A Multi-Center Single Agent Phase II Study of the Efficacy of Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor |
Active, not recruiting |
NCT01207492 |
Phase 2 |
nilotinib |
32 |
A Phase 2, Open-Label, Adaptive, Dose-Ranging Study With Long-Term Extension to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of Intra Articular AMB-05X Injections in Subjects With Tenosynovial Giant Cell Tumor |
Not yet recruiting |
NCT05349643 |
Phase 2 |
|
33 |
Investigation of the Use of Positron Emission Tomography With 18F-FDG PET/CT for the Diagnosis of Synovitis in the Temporomandibular Joint |
Withdrawn |
NCT01471418 |
Phase 2 |
PET/CT with 18-FDG |
34 |
A Phase 1 Study to Assess Safety, Pharmacokinetics, and Pharmacodynamics of PLX73086 as a Single Agent in Subjects With Advanced Solid Tumors and in Subjects With Locally Advanced or Refractory Tenosynovial Giant Cell Tumor (TGCT) |
Terminated |
NCT02673736 |
Phase 1 |
PLX73086 |
35 |
A Pilot Study About the Safety and Efficacy of Intra-articular Bevacizumab (Avastin) for Recurrent Hemarthroses at Target Joints With Chronic Hemophilic Synovitis |
Terminated |
NCT02060305 |
Phase 1 |
Bevacizumab intra-articular injection |
36 |
Evaluation of the Effectiveness of Surgical Treatment of Villo-nodular Synovitis of the Hip in Children in a Retrospective Case Series |
Unknown status |
NCT03507933 |
|
|
37 |
Computer-Assisted Quantification of the Synovial Perfusion in Patients With Arthritis Using Two-Dimensional and Three-Dimensional Power Doppler Ultrasonography |
Unknown status |
NCT00903903 |
|
|
38 |
Does Synovitis Affect Treatment Efficacy in Intra-articular Injection Therapy to Osteoarthritis |
Unknown status |
NCT03167333 |
|
platelet rich plasma;Hyaluronic acid |
39 |
Preliminary Study of Sonic Hedgehog Signaling Pathway in the Pathogenesis of Rheumatoid Arthritis |
Unknown status |
NCT01731262 |
|
|
40 |
Characterizing Synovitis, Acne, Pustulosis, Hyperostosis, and Osteitis (SAPHO) With 68Ga-FAPI PET/CT |
Unknown status |
NCT04596462 |
Early Phase 1 |
68Ga-FAPI |
41 |
A Clinical Study of Subclinical Enthesitis and Synovitis in Patients With Vulgaris Psoriasis |
Unknown status |
NCT02339636 |
|
|
42 |
Correlation of "Painless" Synovitis With Clinical, Laboratory and Radiological (X-ray, Sonography) Finds in Patients With Longstanding Rheumatoid Arthritis (RA). |
Unknown status |
NCT01639287 |
|
|
43 |
The Relation Between Dedicated Extremity MRI Synovitis and Structural Deterioration Radiographic in Patients With Rheumatoid Arthritis in Clinical Remission.Preliminary Study |
Unknown status |
NCT01050010 |
|
|
44 |
Efficacy of Kinesio Tape in the Treatment of Medial Plica Syndrome - A Prospective Study |
Unknown status |
NCT04085497 |
|
|
45 |
Using Magnetic Resonance Imaging and DL Methods to Explore the Diagnosis and Clinical Prognosis of Joint Synovitis. |
Completed |
NCT04952896 |
|
|
46 |
Screening of Specific Genes for Pigmented Villous Nodular Synovitis |
Completed |
NCT04955535 |
|
|
47 |
Comparison of the Frequency of Subclinic Synovitis in the Distal Interphalangeal Joints of the Hand in Psoriasis Patients |
Completed |
NCT04750993 |
|
|
48 |
Prognostic Indicators and Determinants of the 2-5 Year Outcome in a Cohort of Early Synovitis Patients |
Completed |
NCT00001679 |
|
|
49 |
A Case Control Study to Define Clinical, Immunologic and Radiographic Features of the Aromatase Inhibitor Arthralgia Syndrome |
Completed |
NCT00890058 |
|
|
50 |
Prospective Analgesic Compound Efficacy (PACE) Study |
Completed |
NCT02403687 |
|
baclofen 2%;Bupivacaine hydrochloride 1%;Cyclobenzaprine hydrochloride 2%;Diclofenac Sodium 3%;Flurbiprofen 10%;Gabapentin 6%;Ketamine 10%;Lidocaine 2%;Prilocaine 2.5%;Meloxicam 0.09%;Sumatriptan 5%;Tizanidine 0.1%;Topiramate 2.5%;Capsaicin, USP 0.0375%;Menthol, NF 5.00 % |
|